Opko Health, Inc. (NASDAQ:OPK) has been given a consensus rating of “Buy” by the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $14.72.

A number of brokerages recently issued reports on OPK. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research report on Friday. Barrington Research raised their price target on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday. BidaskClub upgraded Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research report on Friday, June 16th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 5,400 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was acquired at an average cost of $6.46 per share, for a total transaction of $34,884.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $19,825,423.46. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director John A. Paganelli bought 5,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were acquired at an average price of $6.17 per share, with a total value of $30,850.00. Following the completion of the transaction, the director now owns 350,340 shares of the company’s stock, valued at approximately $2,161,597.80. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 2,693,700 shares of company stock valued at $18,080,916. Corporate insiders own 40.19% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in OPK. Vanguard Group Inc. increased its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock valued at $210,576,000 after buying an additional 1,112,843 shares during the last quarter. BlackRock Inc. increased its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after buying an additional 22,449,752 shares during the last quarter. State Street Corp increased its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management increased its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock valued at $40,489,000 after buying an additional 1,944,549 shares during the last quarter. Finally, Norges Bank purchased a new stake in Opko Health during the fourth quarter valued at $30,421,000. Hedge funds and other institutional investors own 23.65% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Opko Health, Inc. (NASDAQ:OPK) Receives Consensus Recommendation of “Buy” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/21/opko-health-inc-nasdaqopk-receives-consensus-recommendation-of-buy-from-analysts.html.

Opko Health (NASDAQ OPK) traded up 3.193% during midday trading on Friday, reaching $6.625. 2,526,109 shares of the company were exchanged. The firm’s market capitalization is $3.71 billion. Opko Health has a 52 week low of $5.99 and a 52 week high of $12.15. The company has a 50-day moving average of $6.48 and a 200 day moving average of $7.57.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The firm’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) earnings per share. Equities analysts predict that Opko Health will post ($0.20) earnings per share for the current year.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.